<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598061</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0521</org_study_id>
    <nct_id>NCT04598061</nct_id>
  </id_info>
  <brief_title>IV Dexmedetomidine as Spinal Anesthesia Adjuvant in Infants</brief_title>
  <acronym>RACHI_dex</acronym>
  <official_title>IV Dexmedetomidine as Spinal Anesthesia Adjuvant in Infants : RACHI_dex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Spinal anesthesia in newborns is one of &quot; Gold standard &quot; techniques in short&#xD;
           subumbilical surgeries (less than 30 minutes) with advantage of avoiding the risks&#xD;
           inherent to general anesthesia.&#xD;
&#xD;
        -  Spinal anesthesia of the newborn remains a complex technical procedure with a failure&#xD;
           rate of up to 16%. The child's movements and certain degrees of discomfort may also&#xD;
           interfere with the successful completion of the procedure.&#xD;
&#xD;
        -  The second major issue of spinal anesthesia is the limitation of the motor block&#xD;
           duration and the need for general anesthesia to complete the surgery&#xD;
&#xD;
        -  Spinal anesthesia duration can be prolonged by the addition of differents adjuvant such&#xD;
           as opioid or alpha 2 adrenergic agonist.&#xD;
&#xD;
        -  Since 2018, dexmedetomidine, an alpha 2 adrenergic agonist with sedative, analgesic and&#xD;
           anxiolytic properties, is being used as a current and standard practice in our&#xD;
           anesthesia department. Intravenous administrationis performed ten to twenty minutes&#xD;
           before spinal anesthesia placement in all children weighing less than 7 kg undergoing an&#xD;
           infra-umbilical surgery of expected duration of less than 1 hour. This strategy ensures&#xD;
           the child's comfort and allows the procedure to be performed under optimal conditions&#xD;
           for practitionner.&#xD;
&#xD;
        -  The objective of this study is to review our practices and to evaluate the impact of the&#xD;
           use of dexmedetomidine during spinal anesthesia of newborns and infants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">November 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>duration of motor block</measure>
    <time_frame>immediately after procedure in the recovery room</time_frame>
    <description>Time at which the motor block is finished</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Newborns</condition>
  <condition>Infant</condition>
  <condition>Spinal Anesthesia</condition>
  <arm_group>
    <arm_group_label>Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery</arm_group_label>
    <description>Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine IV</intervention_name>
    <description>Dexmedetomidine IV</description>
    <arm_group_label>Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All children weighing less than 7 kg undergoing an infra-umbilical surgery of expected&#xD;
        duration of less than 1 hour&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Newborns or Infants&#xD;
&#xD;
          -  less than 7 kg&#xD;
&#xD;
          -  Infra-umbilical surgery less than 1 hour&#xD;
&#xD;
          -  Spinal anesthesia&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  parental refusal&#xD;
&#xD;
          -  Contraindication to spinal anaesthesia (coagulation disorder, ongoing sepsis, spinal&#xD;
             malformation...).&#xD;
&#xD;
          -  Contraindication to Dexmedetomidine (intracardiac conduction disorder, uncontrolled&#xD;
             hemodynamic instability, alertness disorder)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chrystelle SOLA, PH</last_name>
    <role>Study Director</role>
    <affiliation>UH Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chrystelle SOLA, PH</last_name>
    <phone>06 65 84 91 66</phone>
    <email>c-sola@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Montpellier</city>
        <state>HÃ©rault</state>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrystelle SOLA, PH</last_name>
      <phone>06 65 84 91 66</phone>
      <email>c-sola@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>less than 7 kg</keyword>
  <keyword>undergoing an infra-umbilical surgery</keyword>
  <keyword>Spinal anesthesia</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>respiratory complications</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

